<?xml version="1.0" encoding="UTF-8"?>
<p>Glasdegib in combination with cytarabine/daunorubicin has the potential to demonstrate improved OS in patients with AML or high‐risk MDS. Median OS of 14.9 months was achieved with glasdegib 100 mg combined with cytarabine/daunorubicin in the overall patient population and was within the range for OS (6.5‐24.5 months) reported in the literature for patients treated with other AML treatment regimens, including a trial of high‐dose daunorubicin in older patients with AML.
 <xref rid="ajh25238-bib-0002" ref-type="ref">2</xref>, 
 <xref rid="ajh25238-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="ajh25238-bib-0004" ref-type="ref">4</xref>, 
 <xref rid="ajh25238-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="ajh25238-bib-0032" ref-type="ref">32</xref>, 
 <xref rid="ajh25238-bib-0034" ref-type="ref">34</xref>, 
 <xref rid="ajh25238-bib-0037" ref-type="ref">37</xref>, 
 <xref rid="ajh25238-bib-0038" ref-type="ref">38</xref>, 
 <xref rid="ajh25238-bib-0040" ref-type="ref">40</xref>, 
 <xref rid="ajh25238-bib-0041" ref-type="ref">41</xref>, 
 <xref rid="ajh25238-bib-0042" ref-type="ref">42</xref>, 
 <xref rid="ajh25238-bib-0043" ref-type="ref">43</xref> Despite the limited sample sizes, in a 
 <italic>post hoc</italic> analysis, the median OS compared favorably with historical controls across ELN risk groups.
 <xref rid="ajh25238-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="ajh25238-bib-0032" ref-type="ref">32</xref>, 
 <xref rid="ajh25238-bib-0040" ref-type="ref">40</xref>, 
 <xref rid="ajh25238-bib-0041" ref-type="ref">41</xref>, 
 <xref rid="ajh25238-bib-0042" ref-type="ref">42</xref>
</p>
